A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Pancreatic ductal adenocarcinoma (PDAC) exhibits poor survival rates, often linked to KRAS mutations.
• Current RAS inhibitor therapies face limitations due to rapid tumor resistance.
• Targeting KRAS signaling pathways is crucial for effective PDAC treatment.

Purpose of the Study:

• To investigate the efficacy of targeting multiple KRAS signaling nodes (EGFR, RAF1, STAT3) in PDAC.
• To evaluate a combination therapy using selective inhibitors against KRAS, EGFR, and STAT3.
• To assess the durability of treatment response and potential for tumor resistance.

Main Methods:

• Genetic ablation of RAF1, EGFR, and STAT3 in orthotopic PDAC mouse models.
• Pharmacological inhibition of KRAS (daraxonrasib), EGFR family (afatinib), and STAT3 (SD36).
• Assessment of tumor regression, resistance development, and tolerability in various PDAC models, including patient-derived tumor xenografts (PDX).

Main Results:

• Genetic ablation of RAF1, EGFR, and STAT3 led to complete and permanent PDAC regression.
• Combination therapy with daraxonrasib, afatinib, and SD36 achieved complete PDAC tumor regression.
• No tumor resistance was observed for over 200 days post-treatment in orthotopic models.
• Significant regression was observed in genetically engineered mouse tumors and PDX models without relapse.
• The combination therapy was well-tolerated.

Conclusions:

• Targeting KRAS, EGFR, and STAT3 simultaneously is a highly effective strategy for PDAC.
• This combination therapy demonstrates potential for durable, relapse-free tumor eradication.
• The findings support the development of novel clinical trials for PDAC patients.